Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03901378
Title Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ochsner Health System
Indications

gastrointestinal neuroendocrine tumor

large cell neuroendocrine carcinoma

pancreatic endocrine carcinoma

Therapies

Carboplatin + Etoposide + Pembrolizumab

Pembrolizumab

Cisplatin + Etoposide + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.